A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

Also called NCT01307033

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 278 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01307033
Other papers using this trial's data
  • Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials Hypertension research : official journal of the Japanese Society of Hypertension, 2014-12 DOI, PubMed 24990091

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01307033. Randomized; double masking; primary purpose treatment. Start 2011-03-29 (actual); primary completion 2012-12-04 (actual). Results posted on 2014-01-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
Condition
Hypertension
Intervention (Drug)
MK-0954A
Intervention (Drug)
MK-954H
Intervention (Drug)
Placebo to MK-0954A
Intervention (Drug)
Placebo to MK-954H
Lead sponsor
Organon and Co (class: industry)

Record details

Record id
cardio:ct-nct01307033
Content hash
38139f08ca135876eb2ebfc7a9f3aa50d2e47b80d9d82a9586653069548da3c0